Barinthus Biotherapeutics Plc ( (BRNS) ) has released its Q4 earnings. Here is a breakdown of the information Barinthus Biotherapeutics Plc presented to its investors.
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapeutic candidates aimed at treating autoimmune and inflammatory diseases through its proprietary SNAP-TI platform.
In its latest financial report, Barinthus Bio highlighted a strategic transformation towards focusing on immunology and inflammatory diseases, with significant advancements in its lead candidate, VTP-1000, for celiac disease. The company also reported financial results for the year ending December 31, 2024, and shared updates on its corporate developments.
Key financial metrics revealed a decrease in cash reserves to $112.4 million from $142.1 million in the previous year, primarily due to ongoing clinical trials and pipeline development. Revenue saw a substantial increase to $15.0 million, driven by royalties from Vaxzevria® sales. The company reported a net loss of $61.1 million, an improvement from the previous year’s loss of $73.3 million, attributed to reduced research and development expenses.
Strategic announcements included the progression of VTP-1000 into clinical trials for celiac disease, with promising data expected in the third quarter of 2025. The company also reported encouraging results from its VTP-300 trials for chronic hepatitis B, although it plans to seek partnerships for further development. Corporate restructuring efforts are underway to prioritize U.S. operations and focus on immunology.
Looking ahead, Barinthus Bio remains optimistic about its strategic focus on immunology and inflammation, with expectations of leveraging its SNAP-TI platform for future pipeline opportunities. The company anticipates its cash resources will support operations into 2027, as it continues to advance its clinical programs and explore potential partnerships.